厄贝沙坦联合胺碘酮治疗心衰并发室性心律失常的临床效果探讨

Study on Clinical Effect of Irbesartan and Amiodarone in Treatment of Heart Failure and Ventricular Arrhythmias

目的研究厄贝沙坦联合胺碘酮治疗心衰并发室性心律失常的临床效果。方法随机选取2015年10月—2016年10月该院心衰并发室性心律失常患者80例,随机分2组,每组40例,对照组胺碘酮片,观察组再给予厄贝沙坦,对比两组患者的室性心律失常、心功能以及治疗后的HR、LVEF情况。结果观察组心衰并发室性心律失常患者心功能的总有效率为92.50%,室性心律失常控制有效率为87.50%,治疗效果明显优于对照组,差异有统计学意义(P<0.05)。观察组治疗后HR情况为(72.65±4.32)次/min,LVEF情况为(50.66±6.49)%,观察组心衰并发室性心律失常患者的HR、LVEF情况明显优于对照组,差异有统计学意义(P<0.05)。结论厄贝沙坦联合胺碘酮治疗的安全性高,在临床治疗效果中显著,适用于心衰并发室性心律失常的治疗。

Objective To research the clinical effect of irbesartan and amiodarone in treatment of heart failure and ventricular arrhythmias. Methods Random selection 80 cases of patients with heart failure and ventricular arrhythmias admitted and treated in our hospital from October 2015 to October 2016 were selected and randomly divided into two groups with 40 cases in each, the control group were treated with amiodarone tablets, while the observation group were treated with irbesartan, and the ventricular arrhythmias, heart function and HR and LVEF after treatment were compared between the two groups. Results The total effective rate of heart function of patients with heart failure and ventricular arrhythmias in the observation group was obviously better than that in the control group（92.50% vs 87.50%）, and the difference had statistical significance（P〈0.05）, and the HR and LVEF after treatment in the observation group [（72.65 ±4.32）times/min,（50.66 ±6.49）% ] were obviously better than those in the control group, and the differences had statistical significance（P〈0.05）.Conclusion The safety of irbesartan and amiodarone in treatment of heart failure and ventricular arrhythmias is high, and the clinical treatment effect is obvious, which is suitable for the treatment of heart failure and ventricular arrhythmias.